Avidity Biosciences Inc [RNA] stock is trading at $44.02, down -1.03%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RNA shares have lost -4.78% over the last week, with a monthly amount glided 29.39%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Bernstein started tracking the stock with Outperform rating on June 24, 2025, and set its price target to $50. On June 17, 2025, Wolfe Research initiated with a Outperform rating and assigned a price target of $55 on the stock. Raymond James started tracking the stock assigning a Strong Buy rating and suggested a price target of $65 on June 11, 2025. Citigroup initiated its recommendation with a Buy and recommended $70 as its price target on March 13, 2025. BMO Capital Markets started tracking with a Outperform rating for this stock on March 12, 2025, and assigned it a price target of $72. In a note dated March 07, 2025, Scotiabank initiated an Sector Outperform rating and provided a target price of $70 on this stock.
Avidity Biosciences Inc [RNA] stock has fluctuated between $21.51 and $56.00 over the past year. Currently, Wall Street analysts expect the stock to reach $70 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $44.02 at the most recent close of the market. An investor can expect a potential return of 59.02% based on the average RNA price forecast.
Analyzing the RNA fundamentals
Avidity Biosciences Inc [NASDAQ:RNA] reported sales of 10.73M for the trailing twelve months, which represents a growth of 88.12%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -48.63%, Pretax Profit Margin comes in at -42.48%, and Net Profit Margin reading is -42.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.33 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.88 points at the first support level, and at 41.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 44.96, and for the 2nd resistance point, it is at 45.89.
Ratios To Look Out For
For context, Avidity Biosciences Inc’s Current Ratio is 9.26. As well, the Quick Ratio is 9.26, while the Cash Ratio is 1.81. Considering the valuation of this stock, the price to sales ratio is 527.80, the price to book ratio is 4.46.
Transactions by insiders
Recent insider trading involved McCarthy Teresa, Chief Human Resources Officer, that happened on Aug 15 ’25 when 10000.0 shares were sold. Officer, TERESA MCCARTHY completed a deal on Aug 15 ’25 to buy 45000.0 shares. Meanwhile, Chief Financial Officer MacLean Michael F sold 30914.0 shares on Aug 06 ’25.
